ClinicaliQ Trial Snapshot
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07705555.
- What is being tested: MK-8748, a novel investigational therapy, is being compared against aflibercept (standard treatment) to evaluate its efficacy and safety in treating diabetic macular edema (DME).
- Patient eligibility overview: The trial recruits participants with diagnosed diabetic macular edema who are eligible for anti-vascular endothelial growth factor (anti-VEGF) treatment, comparing outcomes between the new agent and established standard care.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
Eligibility Snapshot
- : The main inclusion criteria include but are not limited to the following: * Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12% * Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME) * For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.